Bill C-47, "An Act to implement certain provisions of the budget tabled in Parliament on March 28, 2023," aka "Budget Implementation Act, 2023, No. 1" is an omnibus bill that includes proposed amendments...

As previously reported, the Federal Court of Appeal (FCA) dismissed Pfizer's appeal from a decision granting Pharmascience's motion for a summary trial on Pfizer's defence of ex turpi causa...

In a press release yesterday, the Québec Government announced that the proposed amendments to the Regulations under the Charter of the French Language will come into force on November 24, 2016.

On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.

CADTH is now known as Canada's Drug Agency (CDA-AMC or CDA). Its mandate extends beyond CADTH's mandate to include...

After filing a new drug submission for its ustekinumab biosimilar PYZCHIVA (Janssen's STELARA), Samsung commenced the underlying action against...

On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list to include the following...

As previously reported, on February 29, 2024, the Minister of Health introduced Bill C-64, An Act respecting pharmacare (Pharmacare Act)...

In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.

Health Canada is launching a consultation on a proposed pilot program that would prioritize generic drug submissions involving domestic manufacturing within its regulatory review queue.

On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) announced that it will launch the first phase of consultations on new guidelines.

On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) announced the release of CompassRx (10th edition), an annual report that analyzes factors driving prescription drug expenditures in Canadian public drug plans.

On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines

On June 20, 2023, the Patented Medicine Prices Review Board (PMPRB) released a proposal to amend the Interim Guidance...

As previously reported, the Federal Court of Appeal dismissed two decisions relating to paliperidone palmitate (Janssen's INVEGA SUSTENNA)...

In the Patented Medicine Prices Review Board (PMPRB)'s June 2025 NEWSletter, Acting Chairperson Anie Perrault confirms that the PMPRB plans on publishing its final Guidelines in summer 2025.

Principal Christian Bolduc discusses the impact of Bill 96 on trademark protection for businesses operating in Québec in an interview with Managing IP (MIP).

The Government of Canada has initiated a comprehensive public consultation to examine whether geographical indications protection should extend beyond wines, spirits, agricultural products and food to include traditional craft and industrial products. This review marks the first major assessment of Canada's GI regime since 2017 and could align the country with jurisdictions like the European Union, which recently implemented a framework for protecting craft and industrial geographical indications.

Le 25 juillet 2025, le Bureau des médicaments brevetés et de la liaison de Santé Canada a publié son Rapport statistique 2024/2025 pour le Règlement sur les médicaments brevetés (avis de conformité)...

Hear from Janice Bereskin as she discusses the valuable institutional knowledge of IP and the highlights of the INTA 2023 conference in Singapore, in the special podcast series...